The purpose of this study is to: 1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with rituximab or not in young mantle cell lymphoma patients (age≤65 years); 2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance regimens.
Enrolled patients will receive EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) ±R /DHAP(cisplatin, cytarabine and dexamethasone) ±R alternating chemotherapy. If a partial remission or better response achieves, patients will be recommended to receive autologous stem cell transplantation as consideration therapy or another two cycles EDOCH ±R /DHAP±R chemotherapy (based on patient's choice). Patients with less than partial remission (PR) response will quit this study. After treatments finished, maintenance therapy with rituximab or thalidomide plus prednisone will be given less than two years. The determination of maintenance regimens is dependent on patients choices.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
55
Shuhua Yi
Tianjin, China
progression free survival
the time interval between diagnosis and disease progression or death or last follow-up
Time frame: up to 36 months
complete remission
measure with normal serum immunofixation electrophoresis and normal bone marrow feature, and without symptoms and enlarged organs
Time frame: up to 6 months
overall survival
time interval between diagnosis and death or last follow-up
Time frame: up to 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
0.4 mg/m2, IV, d1-4
750 mg/m2 ,d5
2g/m2, q12h, d1
100mg/ m2,IV, d1
375 mg/m2 IV, d1
50-150mg/d, po, d1-28
0.5mg/Kg, po, qod